Silexion Therapeutics Reports $2.7 Million Net Loss in Q1 2026

Silexion Therapeutics Corp reported a net loss of $2.7 million for the first quarter of 2026, an increase from a loss of $1.7 million during the same period in 2025. The company's total operating expenses rose to $2.7 million, up from $1.7 million year-over-year, primarily driven by increased research and development costs associated with preparations for clinical trials of its lead product candidate, SIL204. Research and development expenses surged by 133% to $1.4 million, reflecting significant investments in subcontractor services and toxicology studies. General and administrative expenses also increased by 27% to $1.4 million, largely due to higher professional service costs and share-based compensation.

In terms of financial position, Silexion's cash and cash equivalents stood at $2.4 million as of March 31, 2026, a decrease from $6.1 million at the end of 2025. The company experienced negative cash flows from operating activities of $3.6 million during the quarter, compared to $2.5 million in the prior year. The decline in cash reserves is attributed to increased prepayments for research and development activities, particularly related to the upcoming clinical trials. The company has not generated any revenue to date and continues to rely on external financing to support its operations.

Strategically, Silexion has made significant moves to bolster its financial standing, including entering into an At The Market (ATM) Offering Agreement, which allows for the sale of up to $13.17 million in ordinary shares. In the first quarter of 2026, the company raised approximately $0.08 million through this mechanism. Additionally, Silexion completed a series of warrant exercise transactions, raising $1.0 million in May 2026. The company also approved an increase in its authorized share capital to facilitate future financing efforts.

Operationally, Silexion is focused on advancing its clinical programs, particularly for SIL204, which targets KRAS-driven cancers. The company has initiated preparations for clinical trials expected to begin in the second quarter of 2026, pending regulatory approval. As of May 14, 2026, Silexion had 4,189,954 ordinary shares outstanding. The company is classified as a smaller reporting company and an emerging growth company, which allows it to take advantage of certain regulatory exemptions.

Looking ahead, Silexion's management has expressed substantial doubt about the company's ability to continue as a going concern without additional financing. The company is actively exploring various funding options to support its ongoing research and development activities and to maintain compliance with Nasdaq listing requirements. The financial outlook remains contingent on successful capital raises and the progression of clinical trials for SIL204.